Copenhagen, Denmark, December 19, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”)...
Author - David Miller
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for...
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced...
Physical Activity Linked to Attenuation of Colon Cancer Survival...
MONDAY, Feb. 24, 2025 -- For patients with stage III colon cancer participating in clinical trials...
Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15...
CHATHAM, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq:...
Lexicon Announces Receipt of Complete Response Letter for...
THE WOODLANDS, TEXAS, DEC. 20, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today...
Muscle-Building Supplements Tied to Muscle Dysmorphia...
MONDAY, Feb. 24, 2025 -- The use of multiple muscle-building supplements is associated with muscle...
2.3 Million New Female Breast Cancer Cases Seen Globally in 2022
MONDAY, Feb. 24, 2025 -- In 2022, there were 2.3 million new breast cancer cases and 670,000 deaths...
Depression Risk Lower With GLP-1 Receptor Agonists Versus DPP-4...
MONDAY, Feb. 24, 2025 -- For older adults with type 2 diabetes (T2D), use of glucagon-like...
Yogurt Intake-Colorectal Cancer Link Differs by Abundance of...
TUESDAY, Feb. 25, 2025 -- The association of long-term yogurt intake with colorectal cancer...
Glaukos Submits New Drug Application to U.S. FDA for Epioxa
ALISO VIEJO, Calif.–(BUSINESS WIRE) December 23, 2024 — Glaukos Corporation (NYSE:...